Physician profile
Mark H Chaitowitz
NPI 1922215680
$13,260.95
in general payments reported to CMS, 2019-2025
13 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.87 · 2021: $5,053 · 2022: $3,815 · 2023: $4,167 · 2024: $15.00 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,500 · Food and Beverage: $538 · Travel and Lodging: $290 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,500.00 |
| Food and Beverage | $537.97 |
| Travel and Lodging | $290.38 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $12,989.96 | 2021-2023 | Monoferric |
| Medtronic, INC. | $83.17 | 2025 | Emprint, Osteocool Rf Ablation System |
| Stemline Therapeutics INC. | $30.61 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $27.19 | 2025 | Blenrep, Ojjaara |
| Deciphera Pharmaceuticals INC. | $26.66 | 2023 | Qinlock |
| Geron Corporation | $20.34 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $20.18 | 2019 | |
| Daiichi Sankyo INC. | $18.23 | 2019 | |
| Sobi, INC | $18.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $11.46 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chaitowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.